G

Galecto, Inc.

58 employees

Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Galectin modulators
Myelofibrosis
Oncology
Inflammation
Liver fibrosis
LOXL2
Health Diagnostics
Health Care
Galectin-3 inhibitors
Fibrosis treatment
IPF

Date founded

2011

Funding rounds raised

Total raised

$90M

from 21 investors over 21 rounds

G

Galecto, Inc. raised $64M on September 25, 2020

Investors: Maverick Ventures, Ysios Capital, Novo Holdings, OrbiMed Advisors, Sunstone Life Science Ventures, Seventure Partners, Soleus Capital Management, L.P. and Sphera Fund

G

Galecto, Inc. raised $90M on October 26, 2018

Investors: Maverick Ventures, Sunstone Life Science Ventures, M Ventures, Seventure Partners, Novo Holdings, Ysios Capital and Bristol-Myers Squibb, UK

G

Galecto, Inc. raised $6.3M on October 30, 2013

Investors: SEED Capital Denmark, Bay City Capital, Novo Holdings and M Ventures

G

Galecto, Inc. raised undisclosed on January 2, 2012

Investors: Novo Holdings and M Ventures

FAQ